It looks like the initial hearing in 4/14 because they want to hurry up and decide if there is merit in the case. If there is an injunction, Abilify may be delayed in going generic. If you read the link in that article to the actual lawsuit, it's pretty sound legal work. Also, the lead attorney for the firm worked at the FDA, so he fully understands regulatory process, including complex orphan drug status.
At the end of the day, you know that if you sold a drug for something that wasn't in your label, your company would get fined in a heartbeat. What just happened is that the FDA basically ignored that these studies needed to be submitted in the SNDA and changed the label two months later because they claimed they made a mistake. No, no one submitted two well controlled studies in adults for Tourette's.
It's fascinating; but I would pay attention. Lauroxil is submitting one study because they are using the body of the aripiprazole evidence as support for their NDA. If Abilify is not generic, you are violating the patent. And, if you go at risk before this is resolved, and Otsuka wins, triple damages, baby.